S-1/A: Profusa Amends S-1, Details $120M Capital Raise Efforts

Profusa, Inc. filed an S-1/A to update accounting consent and correct offering expenses, while detailing significant capital raising activities through convertible notes and an equity line of credit.

Summary

• Amendment No. 1 to Form S-1 was filed to replace the Consent of Independent Registered Public Accounting Firm and correct certain estimated offering expenses.
• Estimated total expenses for the offering are $387,445.00, including $100,000.00 for accountants fees and $232,000.00 for legal fees.
• Profusa entered into a PIPE Subscription Agreement on February 11, 2025, with Ascent Partners Fund LLC for up to $22,222,222 in senior secured convertible notes, with an initial closing of $10,000,000 principal for $9,000,000 on July 11, 2025.
• The PIPE notes carry a 10% annual interest rate (24% upon default), a 10% original issue discount, and conversion price protections including down-round and most-favored nation clauses.
• The PIPE agreement was amended multiple times (August 25, December 22, December 29, 2025) to restructure tranches, modify conversion price provisions, and adjust the Floor Price, including a temporary reduction to $0.111 per share for up to 182,000 shares.
• Profusa also established a Committed Equity Facility (ELOC) on July 28, 2025, with Ascent, allowing the company to sell up to $100,000,000 of common stock at its discretion over 36 months.
• Commitment Warrants to purchase 12,000 shares at $0.75 per share were issued to Ascent for the ELOC, with a potential reduction to 6,000 shares if no purchases occur within 100 days.
• The ELOC agreement also included a temporary Floor Price modification to $0.111 per share for up to 182,000 shares, reverting to $0.14 per share after the Modification Period or cap is reached.
• A reverse stock split is expected to be presented to stockholders in January 2026, which marks the end of the temporary Floor Price modification period.
• A License Agreement with Mayo Foundation for Medical Education and Research was executed on February 11, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a low sentiment score due to the highly dilutive nature of the financing agreements, the need for multiple amendments to secure capital, and the explicit mention of an upcoming reverse stock split, all of which suggest significant financial challenges and potential shareholder value erosion.

Positives

• Secured significant potential funding through a PIPE transaction ($22.2M principal) and a Committed Equity Facility ($100M), providing capital for operations.
• The company has flexibility in drawing down funds from the ELOC over 36 months, allowing for strategic timing based on market conditions.
• The filing includes a License Agreement with Mayo Foundation for Medical Education and Research, suggesting potential for product development or commercialization.

Negatives

• The terms of the PIPE convertible notes, including a 10% original issue discount, 10% annual interest (24% on default), down-round protection, and a low conversion price, are highly dilutive and unfavorable to existing shareholders.
• Multiple amendments to the PIPE and ELOC agreements, particularly those lowering the Floor Price and adjusting conversion terms, suggest difficulty in securing capital on more favorable terms and potential pressure on the stock price.
• The expectation of a reverse stock split in January 2026, often a measure to maintain listing compliance, indicates a significantly depressed share price.
• The company is incurring substantial expenses for the offering, including $100,000 for accountants and $232,000 for legal fees.
• The mandatory prepayment terms for subsequent offerings under the PIPE notes (33.3% to 50% of net proceeds) could limit the effectiveness of future capital raises.

Risks

• Significant shareholder dilution from the conversion of PIPE notes and sales under the ELOC, especially given the low conversion prices and floor prices.
• Potential for further stock price decline due to the dilutive nature of the financing agreements and the anticipated reverse stock split.
• Risk of not meeting conditions for subsequent tranches of the PIPE notes (e.g., Nasdaq listing deficiency, stockholder approval, S-1 effectiveness), which could limit access to committed capital.
• High interest rates on convertible notes (10% standard, 24% on default) increase financial burden.
• The SEC's opinion that indemnification for Securities Act liabilities is against public policy means directors and officers may not be fully protected in certain legal actions.

Future Outlook

Profusa expects to present a reverse stock split to its stockholders for approval in January 2026. The company intends to use any proceeds from sales under the Committed Equity Facility for working capital and general corporate purposes. Future capital raises may be subject to mandatory prepayment obligations for existing notes.

Industry Context

StockSavvy.ai notes that the significant capital raising activities, particularly through convertible notes with unfavorable terms and a large equity line of credit, are common for early-stage biotechnology or medical device companies like Profusa that require substantial funding for research, development, and potential commercialization. The anticipated reverse stock split, however, often signals challenges in maintaining stock price levels and could be a concern for investors regarding the company's long-term market valuation and listing compliance. The license agreement with Mayo Foundation suggests a focus on medical innovation, a sector known for high capital intensity and long development cycles.

Comparison to Industry Standards

• The financing terms, including a 10% OID and 10% interest rate on convertible notes with strong anti-dilution protections (down-round, MFN), are generally indicative of a company seeking capital under challenging market conditions or with higher perceived risk, often seen in early-stage biotech firms that have not yet achieved profitability or significant revenue.
• For example, similar terms have been observed in financings for companies like Aytu BioPharma (AYTU) or Sorrento Therapeutics (SRNE) during periods of financial strain or significant capital needs, where investors demand substantial protections and returns for their risk.
• The $100 million ELOC is a substantial facility, comparable in size to those secured by other small-cap biotechs, but the low floor price and the need for multiple amendments to terms suggest a more aggressive approach to securing liquidity than typically seen in more mature or less capital-constrained industry players.

Corporate Governance

Stakeholder Impact

• Shareholders: Significant potential for dilution due to the convertible notes with unfavorable terms (OID, high interest, down-round protection) and the large equity line of credit. The anticipated reverse stock split also signals potential value erosion.
• Creditors (Ascent Partners Fund LLC): Positioned favorably with senior secured convertible notes, high interest rates, default interest, and strong anti-dilution protections.
• Management/Directors: Indemnification provisions are in place under Delaware law, but the SEC's stance on Securities Act liabilities means they may not be fully protected in all legal scenarios.

Next Steps

• The Registration Statement needs to become effective, potentially requiring further amendments.
• Profusa expects to present a reverse stock split to its stockholders for approval in January 2026.
• The company may proceed with the Second, Third, and Fourth Tranches of the PIPE transaction, subject to various conditions including S-1 effectiveness, Nasdaq listing compliance, and stockholder approval.
• Profusa has the option to sell shares to Ascent under the ELOC for up to 36 months, depending on market conditions and funding needs.
• The company will continue to file post-effective amendments to the registration statement as required by the Securities Act.

Key Dates

Recommendation

The filing reveals a company in significant financial distress, evidenced by highly dilutive financing terms, multiple amendments to secure capital, and the explicit plan for a reverse stock split. The terms of the PIPE notes and ELOC are heavily skewed in favor of the investor, indicating a desperate need for capital that will likely result in substantial dilution for existing shareholders. The anticipated reverse stock split is a strong negative signal, often preceding further stock price declines. These factors collectively point to a high risk of significant shareholder value destruction, warranting a strong sell recommendation.

Keywords

Profusa, S-1/A, SEC Filing, PIPE Transaction, Convertible Notes, Equity Line of Credit, ELOC, Capital Raise, Dilution, Reverse Stock Split, Ascent Partners Fund, Corporate Finance, Biotech, Medtech, Mayo Foundation, Registration Statement